<DOC>
	<DOCNO>NCT01413711</DOCNO>
	<brief_summary>The primary objective study evaluate vigabatrin pharmacokinetics ( PK ) neonates receive vigabatrin infantile spasm ( IS ) ; determine safety vigabatrin .</brief_summary>
	<brief_title>An Open-Label , Single Multiple Oral Dose Pharmacokinetic Study Vigabatrin Infants With Infantile Spasms</brief_title>
	<detailed_description />
	<mesh_term>Spasm</mesh_term>
	<mesh_term>Spasms , Infantile</mesh_term>
	<mesh_term>Vigabatrin</mesh_term>
	<criteria>The patient 's parent legally authorize representative able read understand Patient Information Sheet Informed Consent Form . The patient 's legally authorize representative sign Informed Consent Form . The patient IS , diagnose accord International League Against Epilepsy ( ILAE ) criterion . The patient full term ( 38 week gestation ) male female , age &gt; =1 month &lt; 6 month time enrollment . The patient 's length body weight gestational age &gt; =5th &lt; =95th percentile , accord Centers Disease Control Prevention ( CDC ) Growth Charts . The patient currently treat previously treat vigabatrin . The patient member site personnel 's immediate family . The patient take take disallowed recent concomitant medication anticipate patient require treatment least one disallow concomitant medication study . The patient history severe drug allergy hypersensitivity , know hypersensitivity investigational medicinal product ( IMP ) excipients ( povodone/iodine ) IMP . The patient disorder treatment take priority treatment IS likely interfere study treatment impair treatment compliance . The patient treat IMP within 30 day 5 half life ( whichever longer ) prior Screening Visit . The patient disease take medication could , investigator 's opinion , interfere assessment safety , tolerability , efficacy , interfere conduct interpretation study . The patient diagnose judged investigator anemia . The patient diagnose judged investigator renal insufficiency . The patient 's parent legally authorize representative , investigator 's opinion , unlikely unwilling comply protocol patient unsuitable reason .</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>6 Months</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>IS</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Area curve</keyword>
	<keyword>Maximum plasma concentration</keyword>
	<keyword>Time maximum concentration</keyword>
</DOC>